Top Tweets for #escCongress
【俺のESC no.5 】
いつになくペースが早いですが
第5弾！
というのも、このあと年内まだ、
期待しててほしい面白い企画が続きます。
こうご期待
@tadafumisugimo1, @CardioSM,
@AtsushiSssugi, @nebetake, @kuroda_shunsuke
#ESCcongress
【国家規模で心不全SGLT2薬導入の試験／「ついに来たか」肺動脈カテ除神経試験🫀】
聖路加国際病院・水野篤先生（ @atmizu ）ら第一線のエキスパートが、ESC現地の熱気をお届けする「俺のESC2026」。第5回はHot Line 5・6から、心不全管理の未来とリモート医療に迫る10演題を深掘りします👇
・EMAIL-HF：デジタル遠隔介入で心不全患者のSGLT2阻害薬導入率が倍増！
・Remote Exercise SWEDEHEART：AMI後の遠隔リハビリ追加プログラムの意義
・ADHERE-ASCVD：デジタル介入によるスタチン服薬アドヒアランス改善効果
・VIRTUES ICD/PM：デバイス患者の遠隔モニタリング。対面診療との非劣性は
・H-HeFT & Meta-Analysis：HFrEFへのヒドララジン＋硝酸イソソルビド（H-ISDN）。約7年の追跡が示す真価とは
・Met-HeFT & Meta-Analysis：HFrEFへのメトホルミン投与の是非
・LUMINARA：経口リラキシン受容体作動薬の可能性
・PADN-PH-LHD：左心疾患に伴う肺高血圧症へのカテーテル肺動脈除神経術（PADN）
・TIME-HF：看護師主導モバイルヘルス連携ケアが総死亡率を有意に低下！
いつにも増して盛りだくさんな試験数ですが、研究者の底知れぬ熱意を感じた先生たちが揃って「発表だけでなく論文を読んでみたい！」と盛り上がっている場面も必見です❤️🔥動画はこちらから📺
https://t.co/nH6BgWBFZA
LDL-C management in coronary artery disease: Should it begin in the cath lab?
Highlights from a satellite symposium at #ESCCongress 2026
EVOLVE-MI and Real-World Evidence: From Trial Signal to System Change:
- Trial data may shift the treatment paradigm from a "titrate over time" approach to a "just give it" strategy
- Immediate therapy for plaque stabilization may be beneficial, irrespective of LDL-C level at presentation
📺 Find out more in this video from Prof. Marc Bonaca
Watch the full symposium on ESC 265: https://t.co/WCE2goWCJi
Brought to you by COR2ED Medical Affairs in collaboration with Amgen
#MedEd #CardioTwitter #MedTwitter #Cardiology #Coronary #LDLC
Original Article: Tricuspid-Valve Intervention in Heart Failure (TRIC-I-HF trial) https://t.co/reRyqsYCVu
Editorial: Transcatheter Tricuspid-Valve Intervention for Severe Tricuspid Regurgitation https://t.co/yUdFaYqQJt
#Cardiology #ESCCongress
Flashback to #ESCCongress 2026! New REDUCE-IT® analyses offer further insights into the cardiovascular effects of icosapent ethyl.
Hear experts @VietHeartPA and @DLBHATTMD discuss the latest findings and potential implications for patient care in this free, on-demand webcast brought to you by @APAC_Cardiology.
Watch: https://t.co/mOfF20lH9V
【ESC Congress 2026】A Japanese single-center study demonstrated that left atrial pressure increased significantly after pulsed field ablation (PFA) for atrial fibrillation (AF), while there were no differences in ...(continue)
▼https://t.co/86PoxOo0pr
#ESCCongress #ESC2026
Highlights from a satellite symposium at #ESCCongress 2026
Prof. Gilles Montalescot explains how:
➡️ AMUNDSEN trial findings show that initiating evolocumab immediately in the cath lab is both feasible AND significantly more effective than the current guideline-recommended approach + can improve CV outcomes
➡️ Earlier/wider use of PCSK9i is necessary to get high LDL-C levels to target in more patients
Watch video for more details 📺
Watch the full symposium on ESC 265: https://t.co/WCE2goWCJi
Brought to you by COR2ED Medical Affairs in collaboration with Amgen
#MedEd #CardioTwitter #MedTwitter #Cardiology #Coronary #LDLC
🗣️ “Within the limitation of premature termination of the trial, there was a consistent signal for more bleeding complications without a sign of benefit with respect to ischemic complications,” Konstantinos D. Rizas, MD, said at #ESCCongress
https://t.co/XYUWwEbQa4
Want to hear about emerging approaches for AL #amyloidosis? 🩸
@Ron_Witteles of @StanfordDeptMed discussed this at #ESCCongress. Click here for his expert insights:
🎥 https://t.co/2G2hnyDKhe
@escardio #HemOnc #Hematology #CardioOnc
Expert insights on LDL-C management in coronary artery disease
Highlights from a satellite symposium at #ESCCongress 2026
Prof. Ulrich Laufs explains how:
-Advanced plaque imaging is essential to identify dangerous lipid-rich plaques that can be modified through intensive therapy
-VESALIUS-CV shows that lowering LDL-C to v. low levels w/ evolocumab reduces mortality in high-risk pts even before a first major CV event
-Visually showing plaque to pts significantly improves medication adherence + streamlines pt communication
📺 Prof. Lauf’s update in this post
Watch the full symposium on ESC 265: https://t.co/WCE2goXayQ
Brought to you by COR2ED Medical Affairs in collaboration with Amgen
#MedEd #CardioTwitter #MedTwitter #Cardiology #Coronary #LDLC
How can professional societies move beyond conversation and take action to improve women’s health, strengthen women’s leadership, and reduce the global burden of CVD?
Catch up on the RISE @ ESC Congress 2026 session here: https://t.co/tsMWAmYuHC
#LetsRISE26 #ESCCongress
【俺のESC no.4 】
とうとう来ました！その4
我らが中澤先生のPremium 試験を含みます
https://t.co/ITviNB4l0s
Premiumは皆さん散々聞いているかもですので
それ以外のセッションをぜひ！！
@tadafumisugimo1, @CardioSM,
@AtsushiSssugi, @nebetake, @kuroda_shunsuke
#ESCcongress
【出血しない抗凝固薬、待たれる？／日本発！STEMI PCI後アスピリン完全省略の是非🫀】
聖路加国際病院・水野篤先生（ @atmizu ）ら第一線のエキスパートが、ESC現地の熱気をお届けする「俺のESC2026」。
第4回はHot Line 3・4から、ACSと抗血栓・PCI戦略の最前線に迫る怒涛の8演題を深掘りします👇
・LIBREXIA ACS：第XI因子阻害薬Milvexian。出血しない抗凝固薬の夢は？
・PREMIUM：STEMIのPCI直後からアスピリンを完全省略！その安全性と虚血リスクのトレードオフは
・SWITCH SWEDEHEART：ACS後のチカグレロルからプラスグレルへのスイッチ戦略
・A-CLOSE：高リスクPCI後のDAPT延長 vs クロピドグレル単剤療法の行方
・EPIDAURUS：AF合併ACS患者の1ヶ月強力SAPT+DOAC療法
・PRESC1SE-MI：胸痛患者への超迅速0/1hトロポニンアルゴリズムの非劣性を検証
・AIR-STEMI：プレホスピタル迅速評価によるSTEMI再灌流時間短縮の効果
・TARGET-CTCA：ACS疑い・MI除外後の冠動脈CTAガイド治療の長期予後
目まぐるしく変わる抗血栓療法の最新動向や先生たちが日々向き合う課題がまさに検証されているRCTもあるかもしれません。第一線の先生たちによる超速勉強会を体験しませんか。動画はこちらから📺https://t.co/mekT5hmPzr
📢 The results of the EPIDAURUS trial that evaluated the optimal antithrombotic regimen in patients with AF and ACS undergoing PCI was prematurely terminated due to safety concerns from the data and safety monitoring board.
#ESCCongress @escardio #ESC365
https://t.co/BcdEBdjRI1
【ESC Congress 2026】The PADN-HF-PH trial demonstrated that pulmonary artery denervation reduced the risk of clinical worsening in patients with pulmonary hypertension associated with left heart failure receiving ...(continue)
#ESCCongress #ESC2026
▼
https://t.co/yTN3idD7Rh
❤️ More from #ESCCongress ❤️
Potent P2Y12 inhibition plus direct oral anticoagulation did not lower ischemic risk and increased bleeding risk vs. clopidogrel and DOACs in patients with atrial fibrillation and acute coronary syndrome.
@escardio #ESC365
https://t.co/xJKWbaXfWn
Correspondence: Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310 https://t.co/WCAL8aqz04
#Cardiology #ESCCongress
Highlights from a satellite symposium at #ESCCongress 2026 from Prof. Giuseppe Patti
‘From acute ACS to early lipid intervention: Lessons from ARMYDA and beyond’
Get expert insights on:
-Learnings from FAST-MI & ARMYDA-CATCH regarding the “strike early and strong” approach to treating ACS
-Benefits of early PCSK9i use within 24h of an ACS event
-How upstream evolocumab prior to PCI can improve clinical outcomes
📺 Prof. Patti’s update in this post
Watch the full symposium on ESC 265: https://t.co/WCE2goXayQ
Brought to you by COR2ED Medical Affairs in collaboration with Amgen
#MedEd #CardioTwitter #MedTwitter #Cardiology #Coronary #LDLC
O #CPCinMotion continua!
Catarina Ferreira convida a comunidade cardiovascular a participar no #CPC2027, com as miocardiopatias em destaque.
Numa mensagem gravada no #ESCCongress 2026, em Munique, destaca os ensaios CARDIO-TTRansform e ACACIA-HCM e as questões que colocam sobre o tratamento da amiloidose cardíaca por transtirretina e da miocardiopatia hipertrófica não obstrutiva.
De Munique a Vilamoura, continuamos a discussão no CPC 2027.
📅 18 a 21 de março de 2027
📍 Centro de Congressos do Algarve, Vilamoura
Mais informações em https://t.co/Ez73oxxDaI
@spcardio @escardio
@CatarinaMF1907
At the @Medtronic-sponsored lunch symposium at RISE @ ESC Congress 2026, the message was clear: equity in CV care and careers must move faster.
Practical solutions, from community BP checks to intentional sponsorship, can help women lead & access care.
#LetsRISE26 #ESCCongress
Last Seen Hashtags on Sotwe
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
118.9M followers
Cristiano Ronaldo
@cristiano
114.6M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.5M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.2M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers